Trinity Biotech (NASDAQ: TRIB) — Company Overview, News & Financial Data
Trinity Biotech develops clinical diagnostic products for the healthcare industry, specializing in fast testing solutions.
Trinity Biotech
Trinity Biotech (NASDAQ:TRIB) specializes in the development, manufacture, and marketing of clinical diagnostic products for the healthcare industry. Its offerings cater to the segments of infectious disease, clinical laboratory, and point-of-care. Trinity Biotech is traded on the NASDAQ under the symbol TRIB. The company aims to innovate and expand its diagnostics portfolio, focusing on enhancing healthcare outcomes by providing rapid, reliable testing solutions. With operations and strategic partnerships worldwide, Trinity's projects include advancing diagnostic technologies, improving existing product lines, and achieving operational excellence to meet the evolving needs of the global healthcare market.
Snapshot
Operations
Products and/or services of Trinity Biotech
- HIV rapid test kits for accurate, on-site diagnosis of HIV-1 and HIV-2 infections.
- Clinical chemistry reagents used for routine biochemical analysis to assess various bodily functions.
- Autoimmune diagnostics including assays and instruments for detecting autoimmune diseases.
- Diabetes monitoring tests designed to measure glycated hemoglobin levels, aiding in diabetes management.
- Point-of-care tests for infectious diseases, enabling quick diagnosis of conditions like syphilis and malaria.
- Haemostasis products to aid in assessing blood clotting disorders and managing anticoagulant therapy.
Trinity Biotech executive team
- John GillardPresident, CEO, Company Secretary & Director
- Ronan O'CaoimhFounder, Director & Executive Advisor
- Paul MurphyInterim Chief Financial Officer
- Jacqueline O'NeillDirector of Operations
- Gary KeatingChief Technology Officer
- Eibhlin KellyChief Information Officer
- Jerry LydonHead of North America Commercial Operations
- Jordi RomeroHead of Commercial Operations - Europe
Key financials
Reported results for Trinity Biotech , in USD.
- Market cap
- 5.4M
- Revenue (TTM)
- 43.8M
- P/E ratio
- —
- EPS (diluted, TTM)
- -60.0
- Dividend yield
- —
- Profit margin
- -85.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 43.8M | -11.4M | -37.4M | |
| 61.6M | -21.2M | -31.8M | |
| 56.8M | -27M | -24M | |
| 62.5M | -15.3M | -41M |